user

Susceptibility of HIV-2 to approved and experimental antiretroviral drugs: implications for treatment

被引：0
|
作者：
Witvrouw, M
Pannecouque, C
De Clercq, E
Switzer, WM
Folks, TM
Heneine, W
机构：
[1] Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium
[2] Ctr Dis Control & Prevent, Atlanta, GA USA
来源：
ANTIVIRAL THERAPY | 2002年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
143
引用
收藏
页码：S155 / S155
页数：1
相关论文
共 50 条
  • [21] Dolutegravir for the treatment of HIV-2 infection
    Trevino, Ana
    Cabezas, Teresa
    Belen Lozano, Ana
    Garcia-Delgado, Rosa
    Force, Luis
    Maria Fernandez-Montero, Jose
    de Mendoza, Carmen
    Caballero, Estrella
    Soriano, Vincent
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2015, 64 : 12 - 15
  • [22] Plasma and tissue HIV-1 and HIV-2 viral load in HIV-2 and dual HIV-1/HIV-2 infected individuals: Implications for starting HAART
    Schutten, M
    van der Ende, ME
    Tenner-Racz, K
    Racz, P
    Niesters, HGM
    Osterhaus, ADME
    [J]. AIDS, 2000, 14 : S3 - S3
  • [23] HIV-2 TRANSMISSION - IMPLICATIONS FOR SPREAD OF HIV-1
    OBRIEN, TR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (12): : 903 - 904
  • [24] In Vitro Susceptibility of HIV Isolates with High Growth Capability to Antiretroviral Drugs
    Hinay Jr, Alfredo A. A.
    Kanai, Kyosuke
    Tsuneki-Tokunaga, Akeno
    Komatsu, Mizuki
    Telan, Elizabeth O.
    Kageyama, Seiji
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
  • [25] Characteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study
    Ekouevi, Didier K.
    Balestre, Eric
    Coffie, Patrick A.
    Minta, Daouda
    Messou, Eugene
    Sawadogo, Adrien
    Minga, Albert
    Sow, Papa Salif
    Bissagnene, Emmanuel
    Eholie, Serge P.
    Gottlieb, Geoffrey S.
    Dabis, Francois
    [J]. PLOS ONE, 2013, 8 (06):
  • [26] The problem of resistance to antiretroviral drugs in the treatment of HIV infection
    Subotina, I.
    Kazakova, E. E. I.
    [J]. HIV MEDICINE, 2023, 24 : 348 - 348
  • [27] Antiretroviral Therapy for HIV-2 Infection in Non-Endemic Regions
    de Mendoza, Carmen
    Lozano, Ana B.
    Caballero, Estrella
    Cabezas, Teresa
    Ramos, Jose M.
    Soriano, Vicente
    [J]. AIDS REVIEWS, 2020, 22 (01) : 44 - 56
  • [28] Three Main Mutational Pathways in HIV-2 Lead to High-Level Raltegravir and Elvitegravir Resistance: Implications for Emerging HIV-2 Treatment Regimens
    Smith, Robert A.
    Raugi, Dana N.
    Pan, Charlotte
    Coyne, Matthew
    Hernandez, Alexandra
    Church, Brad
    Parker, Kara
    Mullins, James I.
    Sow, Papa Salif
    Gottlieb, Geoffrey S.
    [J]. PLOS ONE, 2012, 7 (09):
  • [29] Dolutegravir-based Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 (HIV-2) Infection: Progress for People Living With HIV-2
    Gottlieb, Geoffrey S.
    [J]. CLINICAL INFECTIOUS DISEASES, 2023, 77 (05) : 749 - 751
  • [30] Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database
    Jean Ruelle
    François Roman
    Anne-Thérèse Vandenbroucke
    Christine Lambert
    Katrien Fransen
    Fedoua Echahidi
    Denis Piérard
    Chris Verhofstede
    Kristel Van Laethem
    Marie-Luce Delforge
    Dolorès Vaira
    Jean-Claude Schmit
    Patrick Goubau
    [J]. BMC Infectious Diseases, 8
12345